Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

por Tang, Lu, Huang, Zhongpei, Mei, Heng, Hu, Yu
Publicado 2023

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY

por Wang, Xindi, LI, Chenggong, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Xu, Jia, Mei, Heng, Hu, Yu
Publicado 2023

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy

por Wang, Xindi, Li, Chenggong, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Xu, Jia, Mei, Heng, Hu, Yu
Publicado 2023

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy

por Wu, Jianghua, Tang, Lu, Du, Mengyi, Li, Chenggong, Kou, Haiming, Jiang, Huiwen, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Liao, Danying, Xiong, Wei, Mei, Heng, Hu, Yu
Publicado 2023

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

por Zhang, Yinqiang, Li, Chenggong, Du, Mengyi, Jiang, Huiwen, Luo, Wenjing, Tang, Lu, Kang, Yun, Xu, Jia, Wu, Zhuolin, Wang, Xindi, Huang, Zhongpei, Zhang, Yanlei, Wu, Di, Chang, Alex H., Hu, Yu, Mei, Heng
Publicado 2023